Almac Group Expands Asia Pacific Presence with New Regional Headquarters and Clinical Trial Supply Facility in Singapore

Almac Group Expands Asia Pacific Presence with New Regional Headquarters and Clinical Trial Supply Facility in Singapore

Singapore, 10 July 2015 – Almac Group, the global contract development and manufacturing organisation, today announced the successful completion of the Health Sciences Authority (HSA) inspection of their new Asia Pacific headquarters in Singapore. 

The new facility, which officially opened on 10 July 2015, enables Almac to expand on the unique suite of clinical trial primary and secondary packaging, distribution, technology and consultation solutions offered from within the region. This allows Almac to even better serve their Asia Pacific pharmaceutical clients either conducting regional trials or expanding to international markets as well as global clients who are conducting pharmaceutical clinical trials in the region.

"Asia Pacific is a vital region for us, as currently 23% of global clinical trials for new pharmaceutical products are being conducted here. By basing our regional headquarters and operations in Singapore, we are better equipped to support our Asia-based clients in their own time zone and languages", said Dr Robert Dunlop, President & Managing Director of Almac's Clinical Services business unit. "With the opening of our new Singapore facility, we are directly supporting studies run by regional and global pharmaceutical firms by providing critical manufacturing, packaging, supply chain management and Interactive Response Technology (IRT) support services in Asia Pacific."

"We welcome Almac's investment into the vibrant ecosystem of biomedical sciences companies in Singapore," said Mr. Kevin Lai, Executive Director of Biomedical Sciences and Consumer Businesses, Singapore Economic Development Board (EDB). "Their decision reinforces Singapore's reputation as a preferred location where companies manage their clinical development and supply chain management for the region and beyond."

The Health Sciences Authority (HSA) inspection of the new facility ensuring standards of safety, quality and efficacy will make Almac the first full service clinical trial packaging and distribution organisation to ever receive GMP certification. This facility strengthens the Group's global footprint with facilities in Europe, the US and Singapore, as well as satellite offices in Japan.

The Singapore facility has full-service equipment which includes primary packaging rooms, secondary packaging areas, frozen storage, label control room, a Just-in-Time (JIT) labelling suite and non-GMP storage area offering clients in the region a streamlined, personalised, turnkey solution which ultimately optimises their clinical trial.

For more information on Almac's Asia Pacific Facility, click here.

About Almac Group 'Partnering to Advance Human Health'

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has organically grown over 30 years and now employs in excess of 3,700 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.